Aurora kinase A inhibition reverses the Warburg effect and elicits unique metabolic vulnerabilities in glioblastoma

• Published in: Nature communications Vol. 12; no. 1; pp. 5203 - 19
• Main Authors: Nguyen, Trang T. T., Shang, Enyuan, Shu, Chang, Kim, Sungsoo, Mela, Angeliki, Humala, Nelson, Mahajan, Aayushi, Yang, Hee Won, Akman, Hasan Orhan, Quinzii, Catarina M., Zhang, Guoan, Westhoff, Mike-Andrew, Karpel-Massler, Georg, Bruce, Jeffrey N., Canoll, Peter, Siegelin, Markus D.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.09.2021; Nature Publishing Group; Nature Portfolio
• Subjects: 13/109; 13/2; 13/31; 13/89; 13/95; 45/15; 45/70; 45/77; 45/88; 45/90; 631/67/1922; 631/67/2327; Aurora kinase; Brain cancer; Chromatin; Fatty acids; Genetic analysis; Glioblastoma; Glioblastoma cells; Glycolysis; Humanities and Social Sciences; Immunoprecipitation; Inhibition; Inhibitors; Kinases; Metabolism; Metabolites; Mitochondria; multidisciplinary; Myc protein; Oxidation; Oxidative metabolism; Oxygen consumption; Proteomics; Receptors; Science; Science (multidisciplinary); Therapeutic targets; Transcriptomes; Transposase
• ISSN: 2041-1723; 2041-1723
• DOI: 10.1038/s41467-021-25501-x

Aurora kinase A (AURKA) has emerged as a drug target for glioblastoma (GBM). However, resistance to therapy remains a critical issue. By integration of transcriptome, chromatin immunoprecipitation sequencing (CHIP-seq), Assay for Transposase-Accessible Chromatin sequencing (ATAC-seq), proteomic and metabolite screening followed by carbon tracing and extracellular flux analyses we show that genetic and pharmacological AURKA inhibition elicits metabolic reprogramming mediated by inhibition of MYC targets and concomitant activation of Peroxisome Proliferator Activated Receptor Alpha (PPARA) signaling. While glycolysis is suppressed by AURKA inhibition, we note an increase in the oxygen consumption rate fueled by enhanced fatty acid oxidation (FAO), which was accompanied by an increase of Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1α). Combining AURKA inhibitors with inhibitors of FAO extends overall survival in orthotopic GBM PDX models. Taken together, these data suggest that simultaneous targeting of oxidative metabolism and AURKAi might be a potential novel therapy against recalcitrant malignancies. Glioblastoma patients are treated with Aurora kinase A (AURKA) inhibitors but resistance can occur. Here, the authors show that AURKA inhibition induces metabolic reprogramming, which leads to increased mitochondrial activity and inhibition of oxidative metabolism sensitizes glioblastoma cells to AURKA inhibition.